ENTX Stock Overview
A clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs where an oral tablet form holds the potential to transform the standard of care. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Entera Bio Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.18 |
| 52 Week High | US$3.35 |
| 52 Week Low | US$0.52 |
| Beta | 1.56 |
| 1 Month Change | 35.09% |
| 3 Month Change | 8.21% |
| 1 Year Change | 294.95% |
| 3 Year Change | -24.48% |
| 5 Year Change | 0.81% |
| Change since IPO | -65.37% |
Recent News & Updates
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate
Dec 07
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate
Jul 12Recent updates
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate
Dec 07We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate
Jul 12Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation
Mar 23We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate
May 31Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?
Feb 15Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?
Oct 13Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M
Aug 11We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully
Jun 10Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth
Jan 21We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow
Oct 06Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation
Jun 19Entera Bio secures European patent for oral PTH formulations
Jun 17We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate
Mar 20Here's Why Entera Bio (NASDAQ:ENTX) Must Use Its Cash Wisely
Dec 05
Shareholder Returns
| ENTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.7% | -3.3% | -0.4% |
| 1Y | 295.0% | -2.7% | 24.8% |
Return vs Industry: ENTX exceeded the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: ENTX exceeded the US Market which returned 24.8% over the past year.
Price Volatility
| ENTX volatility | |
|---|---|
| ENTX Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ENTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ENTX's weekly volatility has decreased from 14% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 19 | Miranda Toledano | www.enterabio.com |
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The company leverage its N-Tab, an oral delivery technology, which is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. Its advanced product candidate is EB613 (oral PTH (1-34)) that is entering into Phase 3 development as the first oral, osteoanabolic (bone-building) once-daily tablet treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis.
Entera Bio Ltd. Fundamentals Summary
| ENTX fundamental statistics | |
|---|---|
| Market cap | US$80.11m |
| Earnings (TTM) | -US$9.18m |
| Revenue (TTM) | US$99.00k |
809.2x
P/S Ratio-8.7x
P/E RatioIs ENTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENTX income statement (TTM) | |
|---|---|
| Revenue | US$99.00k |
| Cost of Revenue | US$90.00k |
| Gross Profit | US$9.00k |
| Other Expenses | US$9.19m |
| Earnings | -US$9.18m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 9.09% |
| Net Profit Margin | -9,270.71% |
| Debt/Equity Ratio | 0% |
How did ENTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 01:26 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Entera Bio Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kalpit Patel | B. Riley Securities, Inc. |
| null null | CG Capital |
| Raghuram Selvaraju | H.C. Wainwright & Co. |